Shots:

• The NMPA has approved AstraZeneca’s fixed-dose combination Xigduo XR (dapagliflozin & metformin hydrochloride extended-release) for adults with T2D as an adjunct to diet & exercise to improve glycaemic control
• The approval was based on a local bioequivalence study and supported by the global diabetes program for Xigduo XR that provided clinical evidence for the efficacy and safety profile of dapagliflozin and metformin IR or XR tablets in patients inadequately controlled on metformin
• Xigduo XR combines two anti-hyperglycemic agents with complementary mechanisms of action: dapagliflozin (approved in China for T2D, HFrEF, and CKD) & metformin hydrochloride (HCl) extended-release. Xigduo XR was approved in the US, Australia & other regions

Ref: AstraZeneca | Image: AstraZeneca

Related News:- AstraZeneca's Farxiga and Xigduo XR Receives FDA's Expanded Label Approval for Type 2 Diabetes (T2D) and Moderate Renal Impairment

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com